Abstract Library

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4470 Demystifying DIPNECH: Updates from a new longitudinal patient registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) was first characterised in 1992 with a case series describing 6 patients with neuroendocrine cell hyperplasia, with cough and dyspnoea. Since that time, DIPNECH has remained understudied.

Conference:

Presenting Author:

Authors: Skotte E, Linden A, Libre M, Lippincott E, Cass A,

Keywords: DIPNECH,

#4024 Management of unresectable insulinoma using cloud-based continuous glucose monitoring: A case report

Introduction: Insulinomas are a rare type of functioning neuroendocrine tumors. Once diagnosed, maintaining normal glycaemic control can be difficult to achieve. Continuous or flash glucose monitoring are now routinely used in the management of type 1 diabetes.

Conference:

Presenting Author:

Authors: Gardner G, Flanagan D, Sherriff D,

Keywords: insulinoma, hypoglycaemia, self-monitoring,

#3738 Breast neuroendocrine carcinoma – A case report

Introduction: Neuroendocrine breast tumors are a rare entity estimated at 0.1% of all breast tumors.

Conference:

Presenting Author:

Authors: Kaid M, Bengueddache A, Kehili H, Bennaoum A, Bereksi-Reguig F,

Keywords: breast neuroendocrine tumor,

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,